

## HEREDITARY CANCER PANEL REQUISITION FORM

ROUTE SAMPLE TO UPMC MAGEE-WOMENS HOSPITAL CYTOGENETICS RM 1217 VIA MEDSPEED COURIER FORM						
MUST BE ENCLOSED WITH SAMPLE AND/OR SECURELY EMAILED TO GenomicsLab@upmc.edu						

PATIENT INFORMATION			REFERRING PHYSICIAN INFORMATION					
First name:		MI:	Last name:	Physician:				
Date of birth:		Sex:	MRN #:	Address:				
Address:		I	City:	City: State:			Zip Code:	
State:	Zip code	2:	Phone:	Phone:	Fax:		1	
Ancestry (check all that apply):			NPI#:					
Ashkenazi Jewish Eastern/Central Europe Middle Eastern Asian Western/Northern Europe Native American Central/South American Other:			Additional Report To:					
SPECIMEN I	NFORM	IATION						
Does this patient have a current or past history of:         Blood transfusion?       Allogenic bone marrow transplant?       Hematologic malignancy?         If the answer is yes to any of these questions, please contact the laboratory to discuss before sending a sample. Peripheral Blood in EDTA (3-5 ml in lavender or pink top tube) preferred. Contact lab before sending other sample types.         STATEMENT OF MEDICAL NECESSITY         By signing, I affirm each of the following:         1. I authorize and direct UPMC Clinical Genomics Laboratory (UCGL) to perform the testing indicated.         2. The testing requested is reasonable and medically necessary, and the test results will impact medical management and treatment decisions for this patient.         3. The patient or legal guardian has been informed of the risks, benefits and limitations of genetic testing and has consented to this test.         4. The person listed as the Ordering Physician is authorized by the law to order the test(s) requested herein.         REQUIRED         Signature of Requesting Physician or Authorized Provider:								
TEST(S) REQUESTED: Hereditary Cancer Gene Panel (Sunquest Code)								
<ul> <li>BRCA1 and BRCA2 Rearrangement Analysis (HCPBRT)</li> <li>BRCA1/BRCA2 Comprehensive Analysis (HCP1)</li> <li>Hereditary Breast Cancer Panel (HCP2)</li> <li>Hereditary Breast and Ovarian Cancer Panel (HCP3)</li> <li>Hereditary Colon Cancer and Polyposis Panel (HCP4)</li> <li>Hereditary Cancer Predisposition Panel (HCP5)</li> <li>Lynch Syndrome Panel (HCP8)</li> <li>Lynch Syndrome Panel (HCP8)</li> <li>Familial Hyperparathyroidism (HCP9)</li> <li>Extended Hereditary Cancer Panel (HCP10)</li> <li>Hereditary Breast and Ovarian Cancer Panel (HCP3)</li> <li>Hereditary Colon Cancer and Polyposis Panel (HCP4)</li> <li>Hereditary BRCA 1/2 Ashkenazi Founder 3-Site Test (HCPAJP)</li> <li>Hereditary Cancer Predisposition Panel (HCP5)</li> </ul>								

*No charge for reanalysis of additional genes within 90 days of initial report.* 

Hereditary Cancer Predisposition Panel (HCP5)
 Hereditary Pancreatic Cancer Panel (HCP6)
 Hereditary Prostate Cancer Panel (HCP7)



UPMC Magee-Womens Hospital UPMC Clinical Genomics Laboratory 300 Halket Street Room 4680 Pittsburgh, PA 15213 GenomicsLab@upmc.edu **Phone (412) 641-2949 | Fax (412) 641-2893** 

NIDI	CATIO	N FOR '	TECTIN	
ND	LATIU		I EST III	

Clinical indication: Her	reditary Bre		-		ome/HNPCC (5 gei	ne) 🗌 Familial Ade	nomatous Polyposis
(APC) Treatment plann			static di	sease) 🔄 OTHER:			
Personal History of Cancer: No Yes							
Cancer type	Check all that apply. Add any other relevant information.         Age at Diagnosis						Age at Diagnosis
Breast	Invasive ductal       Invasive lobular       DCIS       Bilateral       Multiple       Metastatic         Triple negative       ≤ 45 years       ≤ 50 years						
Ovary/tubal/peritoneal	Epithelial	Non-epithelial	STIC   Tu	Imor testing: 🗌 MSI-H 🗌 A	bnormal IHC: (describe	pattern)	
Endometrial	Tumor testing	g 🗌 MSI-H 🔲 Abnorma	l IHC: (des	scribe pattern)			
Pancreatic	Exocrine	Neuroendocrine					
Prostate	Gleason s	core ≥ 7 $\Box$ High/Very H	gh NCCN	risk group 🔲 Intraductal/cr	ibiform 🗌 Metastati	ic	
Colorectal	Proximal Tumor testing	Proximal Distal Rectal Multiple Metastatic Tumor testing MSI-H Abnormal IHC: (describe pattern)					
Other cancer(s)	ther cancer(s)						
Polyps	Location: Tot	al adenomas: 🔲 0-10	11-20	) >20 Other histology:			
Pathogenic variant identified	d via tumor see	quencing Tumor type:	Gene	e:			
Other information							
FAMILY HISTORY OF CA	NCER: AT	TACH PEDIGREE O	R COM	PLETE THE CHART BE	LOW		
Relationship to Patier		Maternal/Paternal			r/ Tumor Site		Age at Diagnosis
		□M □P					
Relative with pathogenic	_		s <b>(ATTA</b>	CH REPORT)   GENE:	Variant:	Relationship:	
GENES INCLUDED IN EA		-					
HCPBRT: BRCA1/2 deletion/dupl HCP1: BRCA1, BRCA2 HCP2: ATM, BARD1, BRCA1, BRC HCP3: ATM, BARD1, BRCA1, BRC HCP4: APC, ATM, AXIN2, BMPR1	CA2 , CDH1, CH CA2, BRIP1, CD	H1, CHEK2, DICER1, EPCA	.M, MLH1,	, MSH2, MSH6, NF1, PALB2, P			MAD4 STK11 TP53
HCP5: APC, ATM, AXIN2, BARD1							
NTHL1, PALB2, PMS2, POLD1, PC							
HCP6: APC, ATM, BRCA1, BRCA2 HCP7: ATM, BRCA1, BRCA2, BRIF					D51C. RAD51D. TP53		
HCP8: EPCAM, MLH1, MSH2, MS	SH6, PMS2				2010, 18 (2012), 11 00		
HCP9: AP2S1, CASR, CDC73, CDK HCP10: AP2S1, APC, ATM, AXIN2 GCM2, GNA11, GREM1-SCG5, M RB1, RET, SDHA, SDHAF2, SDHB, HCP11: BAP1, BRCA2, CDK4, CDF	2, BAP1, BARD IAX, MEN1, MI SDHC, SDHD, KN2A, MITF c.9	1, BMPR1A, BRCA1, BRCA ET, MLH1, MSH2, MSH3, SMAD4, STK11, TP53, TS 952G>A, POT1, PTEN, RB1	MSH6, MI C1, TSC2, , TP53	UTYH, NBN, NF1, NTHL1, PAL VHL	B2, PMS2, POLD1, POL		
HCPAJP: BRCA1 c.68_69delAG (a PAYMENT OPTIONS: E							
INSURANCE BILLING (cop					S AND AUTHOR	ZATIONS	
Primary Insurance	,	Insurance ID		Name and DOB of Insure	ed	Patient Relation to I	Policy Holder
Secondary Insurance		Insurance ID		Name and DOB of Insured		Prior Auth # P	rior Auth Date
ICD-10 Code(s) REQUIRED							
INSTITUTIONAL BILLING:	CONTACT L	AB					
Facility Contact Phone Email							
PATIENT BILL: I am electi	ng to self-pa	y. I agree that neither	UPMC CI	inical Genomics Laborator	ry nor I will submit a	claim to my insuranc	e for this test.